Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $470.78, moving -0.07% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.45%.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for vanzacaftor/tezacaftor ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $448.16, moving -1.57% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.96% ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INCORPORATED (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Twin Momentum Investor model based on ...

福泰制药(VRTX) 在2024年的Jefferies工业会议上，高级副总裁Susie Lisa讨论了公司的当前状况和未来方向。她强调了公司在囊性纤维化（CF）治疗领域的 ...